Global Irradiation Apparatus Market Set to Surge Significantly During 2015 – 2023

The global market for irradiation apparatus can be segmented on the basis of application into diagnostic and therapeutic of dental, chiropractic, and industrial research applications. Geographically, this report takes stock of the potential of irradiation apparatus market in all important regions such as North America, Asia Pacific, Europe, and the Middle East and Africa. Currently, North America is the most lucrative regional market for irradiation apparatus, gain traction from high demand for new technology.

This report provides all-inclusive assessment of all factors that may impact the demand in the global irradiation apparatus market, provides evaluations and forecasts of both application and regional segments, and profiles a number of key companies in order to represent the competitive landscape. This report has been developed by a group of professional market research analysts, aspiring to serve as a reliable business tool for its targeted audiences such as manufacturers of these apparatus, traders and distributors, research institutes, government agencies, and regulatory bodies.

Report Overview and TOC: https://www.transparencymarketresearch.com/irradiation-apparatus-market.html

Global Irradiation Apparatus Market: Overview

This report on the global market for irradiation apparatus presents a complete study of notable trends in the market and factors such as growth drivers, restraints, regulations, and competition, which are expected to have a significant influence on the overall future development of the market. The report provides several forward-looking statements denoting the growth prospects of the market and its key segments over the period between 2016 and 2024. A detailed analysis of the recent technological developments to have hit the market, the competitive landscape of the global market, and the regulatory scenario across key regional markets is also included in the report.

Global Irradiation Apparatus Market: Trends and Opportunities

The key forces leading to the increased usage of irradiation apparatus include the advent of new and more convenient product varieties. The easy availability of portable irradiates apparatus has increased their uptake in hospitals and clinics for a variety of purposes including diagnosis, therapeutics, chiropractic diagnosis, and dental diagnosis.

However, the market faces growth restraints such as strict regulatory aspects involved in the usage, storage, sale, and disposal of irradiation apparatus. Moreover, the high costs of these devices is another key restraint challenging the overall growth prospects of the market for irradiation apparatus, especially across developing or less developed economies.

Request brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3981

Global Irradiation Apparatus Market: Geographical and Competitive Dynamics

From a geographical standpoint, the report examines the market for irradiation apparatus across regions such as Asia Pacific, North America, Europe, and Middle East and Africa. Of these, the market in North America is presently the dominant market owing to the presence of some of the world’s leading pharmaceutical companies and thus the vast scope of application of irradiation apparatus in the region. Europe, another leading region in the pharmaceutical sector, is also one of the leading contributors to the overall revenue of the global irradiation apparatus market.

For Specific and Customized requirements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3981

The Asia Pacific market holds a significant future growth opportunity owing to a thriving pharmaceutical industry and rising government interventions aimed at the development of the sector. As a number of international pharma giants extend their roots in the region through high-end manufacturing facilities, the need for irradiation apparatus will be felt at an encouraging pace in the region over the next few years.

Some of the leading players operating in the global irradiation apparatus market are Philips Healthcare, Carestream Health Inc., Agfa Gevaert NV, Toshiba America Medical Systems Inc., Fujifilm Holdings Corporation, Varian Medical Systems Inc., Siemens Healthcare, Hitachi Ltd., and Ziehm Imaging, Inc.

Pre Book full report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=3981&ltype=S

Global Single Agent Chemotherapy Market Estimated to Flourish by 2014 – 2020

The idea of creating a singular therapeutic drug for multiple forms of cancer has been a widely coveted topic in the healthcare industry. Multiple agents have so far been explored as prime contenders for single agent chemotherapy, especially for esophageal cancer and breast cancer. Currently, for esophageal cancer, single agent chemotherapy has been observed to have short lived responses, which is one of the primary reasons for the greater proportion of usage of combinational chemotherapy. A large number of drug combinations in esophageal chemotherapy are based off cisplatin. A similar case is currently made in favor of combinational chemotherapy for metastatic breast cancer, where research shows that combination chemotherapy gives better overall results than the sequential treatment of a patient using single agents.

Report Overview and TOC:https://www.transparencymarketresearch.com/single-agent-chemotherapy-market.html

However, the benefits of combinational chemotherapy do not suffice to answer for the massive risks or side effects that they hold. Combinational chemotherapy is known to hold a much higher rate of toxicity than single agent chemotherapy. The impact of the former is also largely negative on the mental health of a patient along with their social life. This implies a chance of a lower quality of life for the patient after chemotherapy with combination chemotherapy than with single agent chemotherapy.

Single agent chemotherapy refers to the treatment of cancer with a potent single chemotherapy drug instead of multiple chemotherapy agents. Though, the combination chemotherapy is standard treatment method in most of cancer cases, increasing burden of high risk side effects and adverse effects of combination therapy has promoted use of single agent in management of cancer. Single agent chemotherapy offers some advantages as compared to combination chemotherapy treatment such as in reducing negative effects on quality of life by minimizing toxicity and unwanted side effects. Sequential single-agent treatment is also gaining popularity because of the potential merits associated with single-agent chemotherapy. Single agent chemotherapy also allows for greater dose intensity of drug in some severe conditions.

Request brochure:https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3953

High incidence of life threatening adverse effects in many cases of combination therapy and high cost of treatment associated with multiple agents are some of the major drivers of single agent chemotherapy market. Rising number of cancer cases globally will further enhance the growth of this market since chemotherapy is considered to be one of the most effective treatments of the cancer.

According to the Cancer Research U.K., 14.1 million cancer cases were recorded globally in 2012 alone in the U.K. In addition, factors such as less toxicity and impairment of quality of life have widened the acceptance of single agent chemotherapy amongst patients. Furthermore, huge investment in research and development by pharmaceutical companies, extensive academic and industry collaborations and innovation in targeted drug delivery technologies have shown immense possibilities in future growth of single agent chemotherapy market. However, increasing resistance against single chemotherapy agent over the course of treatment and delayed tumor response rate as compared to combination therapy are some of the key factors restraining the growth of single agent chemotherapy.

The global single agent chemotherapy market has been segmented on the basis of major drug classes, type of cancer and chemotherapy drugs.
Major classes of single agent chemotherapy drugs are alkylating agents, anti-tumor antibiotics, mitotic inhibitors, antimetabolites and miscellaneous single chemotherapy drugs. Alkylating agents is the largest segment of single agent chemotherapy market. By type of cancer, single agent chemotherapy market has been segmented into brest cancer, lung cancer, gastrointestinal cancer, genitourinary cancer, head & neck cancer, endocrine cancer, gynecologic cancers, blood cancer, brain cancer and others. Brest cancer constituted the largest segment by type of cancer for single agent chemotherapy market in 2013. Some of the most popular single agent chemotherapy drugs include chlorambucil, fludarabine, bendamustine, mitomycin, teniposide, vinblastine, carboplatin, dacarbazine, procarbazine, doxorubicin, ramucirumab, ado-trastuzumab and imatinib.

For Specific and Customized requirements@https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3953

Based on geography, the single agent chemotherapy market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). The North American region was recognized as the largest single agent chemotherapy market across the globe in 2013, followed by Europe. Ongoing robust research activities for the development of drugs and biologics, high prevalence of cancer and astronomically high healthcare expenditure are some of the major driving factors for growth in these regions. Cancer is the second most common cause of death in the U.S. The National Institutes of Health estimated overall costs of cancer in 2010 at USD 157 billion. Asia-Pacific is expected to be a one of the fastest growing markets during the forecast period from 2014 to 2020. This high growth is primarily due to improving economic condition in countries such as India, China and Malaysia, and large population base in Asia-Pacific region.

Some of the key players operating in this market globally include Sanofi-Aventis, Novartis Pharmaceuticals, Pfizer Inc., Eli Lilly & Co, ImClone Systems Inc., GlaxoSmithKline AstraZeneca, Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceuticals Industries and Roche.

Pre Book full report@https://www.transparencymarketresearch.com/checkout.php?rep_id=3953&ltype=S

Global Nano-Particle Size Analysis Instrumentation in the Life Sciences Market Explores New Growth Opportunities By 2014 – 2020

Nano-particle size analysis instruments are primarily used for detecting the diameter of nanoparticles. Over the past few years, there has been a sharp rise in the adoption of these instruments in the life science sector owing to their high accuracy. Some of the commonly implemented technologies in the analysis are electron imaging technology, microscope technology, gel permeation chromatography, flow cytometry, ultra-centrifugation, and stem instrument. Rapid advancements in these technologies have widened the scope of applications of nano-particle size analysis instruments. Other than the life science sector, their demand is high in the biopharmaceutical sector as well.

Report Overview and TOC: https://www.transparencymarketresearch.com/nanoparticle-size-instrumentation-life-sciences-market.html

The research report is an outcome of the meticulous examination of the various critical aspects of the global nano-particle size analysis instrumentation in the life sciences market including its dynamics and region-wise outlook. Various paid and unpaid sources including white papers, press releases, journals, presentations, and directories were referred to compile this study. The report sheds light on the competitive nature of the market. It analyzes the business strategies and latest developments of the key players in the market. It presents the statistics pertaining to the market in graphical form for a better understanding.

Global Nano-Particle Size Analysis Instrumentation in the Life Sciences Market: Drivers and Restraints

The increasing spending on research and development activities is providing a significant boost to the growth of the global nano-particle size analysis instrumentation in the life sciences market. Emerging economies offer immense growth opportunities and therefore, these countries are likely to witness set up of more life sciences research centers in the coming years. Moreover, the introduction of novel methods for nano particle analysis is augmenting the market.

Request brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3861

The rising awareness regarding the advantages of nano-particle size analysis instrumentation such as the requirement of less product volume, compliance with regulations, and accurate and reliable particle size analysis is also fuelling the market. On the other hand, the high costs of instruments or implementing technologies are keeping the market from realizing its utmost potential.

Global Nano-Particle Size Analysis Instrumentation in the Life Sciences Market: Regional Outlook

The segments analyzed on the basis of geography are Asia Pacific, Europe, North America, and Rest of the World. North America will be a major revenue contributor to the growth of the market. Rapid advancements in nanotechnology along with the continuous efforts of key players to develop novel products are driving the growth of the region. In addition, the growing number of biotechnology start-ups and research facilities is propelling the growth of the region.

Europe will also be a prominent market during the review period. A large number of players are headquartered in the region, which provides it an edge. Moreover, the increasing demand for nano-particle size instrumentation is supplementing the growth of the region.

Asia Pacific will be an emerging market for nano-particle size analysis instrumentation in the life sciences. The launch of new and advanced instruments with enhanced accuracy is working in favor of the growth of the region. Furthermore, the developing healthcare infrastructure coupled with the favorable government initiatives is providing a fillip to the growth of the region.

For Specific and Customized requirements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3861

Global Nano-Particle Size Analysis Instrumentation in the Life Sciences Market: Competitive Landscape

The presence of a large number of regional and global players has rendered the global nano-particle size analysis instrumentation in the life sciences market highly fragmented. The rapid advancements in nanotechnology are intensifying competition among key players. Some of the prominent companies operating in the market are Agilent Technologies Inc., Bruker AXS Inc., Beckman-Coulter Inc., TSI Instruments, Horiba Instruments, ASPEX Corporation, Fluid Imaging Technologies Inc., Hitachi Instruments, and Micrometrics Instrument Corporation.

Pre Book  full report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=3861&ltype=S

Global Kidney Cancer Drugs Market is Anticipated to Grow US$4.5 bn by 2020

A report by Transparency Market Research predicts the global market for kidney cancer drugs to expand at a 6.6% CAGR during the period between 2014 and 2020.

The global kidney cancer drugs market is dominated by a few global giants, namely F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, GlaxoSmithKline plc, and  Pfizer, Inc. This makes the competitive landscape highly consolidated in nature. Competition among the players is stiff too.

Biopharmaceutical behemoth Pfizer, Inc., among them, led the global market for kidney cancer drugs with maximum share in 2013 on the back of Sunitinib and Axitinib, two of the main drugs used for treating kidney cancer. Other big names in the industry, such as Novartis and GSK too are adopting other strategies to increase their geographical outreach. They are focusing on bolstering their distribution networks in the relatively underserved markets in the emerging nations that are seeing an increasing prevalence of kidney cancer cases.

Read Report @ https://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

North America Market Leads on the Back of Commercial Availability of Drugs from Prominent Brands

Depending upon the prominent brands of drugs, the global market for kidney cancer drugs can be segmented into Avastin (Bevacizumab), Afinitor (Everolimus), Inlyta (Axitinib), Torisel (Temsirolimus), Nexavar (Sorafenib), Sutent (Sunitinib), Proleukin (Aldesleukin/Interleukin-2), and Votrient (Pazopanib). Of them, Sutent, which is the marketed version of Sunitinib – Pfizer’s drug in the global kidney cancer drugs market, raked in maximum revenue in 2013. This is because Sutent is mainly prescribed as the first-line of treatment against kidney cancer. Sutent is also among the most studied drugs in its class for multiple indications, as it targets multiple receptor tyrosine kinases (RTKs).

Geography-wise, the key segments of the global market for kidney cancer drugs are North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America, among them, accounts for maximum market share owing to most prominent brands of kidney cancer treatment drugs being commercially available. In addition, a substantial number of patients and a solid healthcare system tailor-made for the pharmaceutical industry is also majorly fuelling the market in the region. North America accounted for 45% of market share in 2013.

Rising Population of Geriatrics Highly Susceptible to Kidney Cancer Driving Market

The global market for kidney cancer drugs is predicted to clock steady growth in the upcoming years because of an increasing geriatric population and higher prevalence of kidney cancer. As per the American Cancer Society, those afflicted with kidney cancer are mostly in the higher age bracket. The average age of people diagnosed with the malady is 64. Kidney cancer is very uncommon in people under the age of 45. The organization also finds that kidney cancer is one of the 10 most common cancers in both men and women.

Approval of novel drug molecules is also serving to catalyze growth in the global kidney cancer drugs market. Posing a challenge to the market, on the contrary, is the growing sales of generic drug variants on account of expensiveness of branded cancer drugs.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=537

A trend noticed in the global market for kidney cancer drugs is the manufacturers shifting their gaze towards developing economies to bring about sales growth.

Global CINV Drugs Market Expected to Grow US$1.88 bn by 2020

The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that the market will reach a valuation of US$1.88 bn by 2020, rising from its 2013 valuation of US$1.28 bn. The market is expected to post a CAGR of 5.7% between 2014 and 2020.

Read Report @ https://www.transparencymarketresearch.com/cinv-market.html

CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the latter occurs within 24 hours of a patient receiving chemotherapy.

Based on the major drugs available on the market currently, the report segments the CINV existing drugs market as follows: Akynzeo (netupitant-palonosetron FDC), Aloxi (palonosetron), Zofran Generic (ondansetron), Emend (aprepitant), and Kytril Generic (granisetron). Drugs in the pipeline that are studied in the report include:  Rolapitant and SUSTOL (granisetron injection extended release).

It is expected that the incidence rate of cancer will soar 17.1 million by 2020. With a growing prevalence rate of cancer across the world, more and more patients are expected to undergo chemotherapy. This alone will be a high-impact driver for the global CINV drugs market. Studies show that nearly 30% of all people suffering from cancer are advised to undergo chemotherapy. Of these, about 70% to 80% patients suffer from CINV.

In the light of these factors, the CINV existing and pipeline drugs market will receive a boost with the expected launch of new drugs such as SUSTOL (APF-530) and rolapitant. The efficacy of pipeline drugs that are at the clinical study stage has been reported to be higher than that of the current CINV treatment drugs on the market. This will likely lead to physicians prescribing newer drugs more as opposed to existing drugs.

The growth of the CINV drugs market is expected to be hampered to some degree by the patents of two leading drugs – Aloxi and Emend – lapsing. This will cause a dip in the revenue of CINV drugs over the forecast period of the report, which ranges from 2014 to 2020.

Studying the market from the regional perspective, the report states that North America was the largest CINV drugs market in 2013 and will remain in this position until 2020. The CINV drugs market in North America will receive a massive boost from rolapitant and SUSTOL. Europe followed North America in terms of CINV drugs revenue in 2013. The alarming increase in cancer cases reported from Asia Pacific and Rest of the World will enable the CINV drugs market to grow vigorously in these markets.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776

Companies that have secured a competitive edge in the global CINV drugs market are: Helsinn Holding S.A., GlaxoSmithKline plc, Merck & Co., Inc. Heron Therapeutics, Inc., and Tesaro, Inc.

Global Wound Dressing Market To be worth US$10.1 bn by 2020

According to the report, the prime factors boosting the market for wound dressings include the globally rising aging population and the growing prevalence of chronic diseases. In addition, the swift healing times brought about by the usage of wound dressings make them useful during emergency care. The rising incidence of wound infections raises the sale of wound dressings, thus having a positive impact on the market. Furthermore, the rising healthcare expenditure and growing awareness amongst patients about the benefits of wound dressings will also stimulate the market for wound dressings in the coming years. On the other hand, factors such as the soaring cost of advanced wound dressings may restrain demand within a number of Asian markets, thus having a negative impact on the overall market.

Read Report @ https://www.transparencymarketresearch.com/wound-dressing-market.html

A new Transparency Market Research report states that the global wound dressing market stood at US$7.5 bn in 2013 and is predicted to reach US$10.1 bn in 2020. It is expected to expand at a CAGR of 4.50% from 2014 to 2020. The title of the report is “Wound Dressings Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020”.

On the basis of type, the wound dressing market is segmented into traditional wound care dressings and advanced wound care dressings. Traditional wound care dressings are further segmented into wound closure products, basic wound care, and anti-infective dressings. Amongst these, within traditional wound care dressings, the segment of basic wound care held the largest share in the market in 2013. This is because basic wound care products have experienced strong sales growth in emerging countries owing to them being easy to utilize. On the other hand, the segment of anti-infective dressings is predicted to experience the highest growth rate in the forecast horizon.

Advanced wound dressings are further segmented into films, foams, hydrofiber, hydrocolloids, collagen, and alginates. Amongst these, on the basis of revenue, the segment of foams emerged as the top segment in the market. This is due to the versatility of foams in terms of healing and applicability and their easy availability in stores. This segment is also expected to experience the highest growth rate in the forecast horizon. The segments of hydrofiber and hydrocolloids are also expected to exhibit an impressive growth rate in the forecast horizon. On the other hand, the segments of collagens, films, alginates, and hydrogels are poised to experience sluggish growth in the coming years.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). In 2013, Asia Pacific led the wound dressings market, while RoW exhibited the highest growth rate in traditional wound dressings and is anticipated to maintain its superiority in traditional wound dressings all through the forecast horizon. This is owing to the presence of price-sensitive markets in the region and low adoption rate of advanced wound dressing technologies owing to low literacy levels. On the other hand, North America, led by the U.S., emerged as the largest market for advanced wound dressings on the basis of revenue and Asia Pacific experienced the swiftest growth and is predicted to lead the global market for wound dressings in the coming years. This is due to the increasing social awareness and the rising number of diabetic patients in the region.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=453

As per the report, the key players operating in the market are 3M Healthcare, Coloplast A/S, ConvaTec, Inc., Johnson & Johnson, Mölnlycke Health Care AB, and PAUL HARTMANN AG, among others.

Global Cosmetic Implants Market to Raise at a CAGR of 5.7% between 2014 – 2020

A report published by Transparency Market Research (TMR), titled “Cosmetic Implants Market – Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2014 – 2020”, studies the global cosmetic implants market covering aspects such as market definition, classification, and the growth trajectory exhibited.

With advanced technology and innovative techniques, it is possible today to aesthetically improve a person’s physical appearance. The advent of cosmetic implants, which are specially designed medical devices placed inside or on the surface of the body, has helped individuals aesthetically replace their damaged body parts and regain their appearance. The demand for cosmetic surgeries is exponentially surging as people seek to enhance their beauty, subsequently fuelling demand in the global cosmetic implants market.

Read Report @ https://www.transparencymarketresearch.com/cosmetic-implants-market.html

As per the findings of the International Society of Plastic and Aesthetic Surgeons (ISAPS), in 2013, more than 23 million individuals underwent surgical and non-surgical cosmetic procedures worldwide. The rising number of cosmetic surgeries conducted around the world is the key factor boosting the global cosmetic implants market. The TMR report pegs the overall value of the global cosmetics implants market at US$2.1 bn in 2013. Rising at a CAGR of 5.7%, the market is anticipated to reach US$3.2 bn by the end of 2020.

Despite witnessing an increasing demand worldwide, the high cost of the devices and risks of malfunctions are the key challenges hampering the market’s growth. Nevertheless, with the growing awareness about cosmetic implants and their benefits, the demand for them is anticipated to rise significantly in the near future.

“The global market for cosmetic implants is highly consolidated in nature and is dominated by a handful of players”, said a lead TMR analyst. For instance, in the dental implants segment 50% of the market is held by Nobel BioCare, DENTSPLY International, and Straumann AG. Other prominent enterprises in the market are Biomet, Inc., Zimmer Holdings, Inc., 3M Health Care, Spectrum Medical Designs, Implantech Inc., and GC Aesthetics. Globally, companies such as Mentor Worldwide LLC, Allergan, Inc., and Sientra, Inc. dominated the market for cosmetic implants.

For the purpose of the study, the report segments the global cosmetics implants market on the basis of sources and applications. Among the implants made from various sources, polymer implants led the market in 2013. Due to further research in this segment and easy access to raw materials, the demand for polymer implant devices will continue to increase during the report’s forecast period. The metal implants segment also considerably aided the expansion of the global cosmetic implants market in 2013. In the application segment, breast implants led the market in 2013. Between 2014 and 2020, the breast implant segment is likely to exhibit a CAGR of 6.6%.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3674

The increasing demand for cosmetic implants and introduction of advanced devices will give an impetus to the global cosmetic implants market during the forecast period. The report presents a comprehensive overview of the global cosmetic implants market. It provides insights into the key factors driving and restraining the market. To study the market’s prevailing competitive landscape, leading companies operating therein are also profiled.

Global Dental Bone Graft Substitutes and other Biomaterials Market to Raise at a CAGR of 10.6% from 2014 to 2020

A new research report published by Transparency Market Research states that the global dental bone graft substitutes and other biomaterials market is expected to grow due to the continuous rise in periodontal (gum) diseases along with growing incidence of dental fractures. The report, titled “Dental Bone Graft Substitutes and other Biomaterials Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”, is available for sale on the company’s website. Expert industry analysts have examined the market with the help of a Porter’s five forces analysis and SWOT analysis to highlight the key trends and dynamics influencing the market.

Read Report @ https://www.transparencymarketresearch.com/dental-bone-graft-substitutes-biomaterials.html

The natural materials segment held a mammoth share in the global dental bone graft substitutes and other biomaterials market in 2013. This segment is further divided into xenografts and allografts. The global market for dental bone graft substitutes and other biomaterials has been estimated to expand at a CAGR of 10.6% from 2014 to 2020.From 2014 to 2020, the xenografts segment is estimated to grow at the highest CAGR of 11.10%. This remarkable growth will be due to the growing preference of tissue banks to collect bone tissues sourced from bovine animals instead of humans. Furthermore, the growing acceptance of grafts from animals is also bolstering the xenografts segment.

On the other hand, the allografts segment will also grow at an accelerated rate due to increasing acceptance amongst patients and tissue compatibility post-transplantation. Additionally, manufacturers are working towards developing allografts that will contribute to winning a larger market share.Regionally, North America and Europe together held over 70% of the revenue in the global dental bone graft substitutes and other biomaterials market. This sizeable share can be attributed to the presence of important players such as DENSTPLY International and Institut Straumann AG. However, analysts predict Asia Pacific will grow at the highest CAGR in the next five years due to the huge geriatric pool and rising dental tourism. Out of all the segments, the ceramics segment will grow at a rapid pace in the near future.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1824

The global dental bone graft substitutes and other biomaterials market report profiles some of the key players such as Medtronic, Inc., ACE Surgical Supply Company, Inc., Biomet, Inc., BioHorizons IPH, Inc., Geistlich Pharma AG, Zimmer Holdings, Inc., DENTSPLY International Inc., DePuy Synthes, and Institut Straumann AG. The report offers an insight into their company profiles, investment outlooks, business and marketing strategies, financial overview, list of existing products and those in the pipeline, and research and development activities. The report gives a comprehensive overview of the competitive landscape of the global dental bone graft substitutes and other biomaterials market with the help of a SWOT analysis and Porter’s five forces analysis.

Global Home Healthcare Market is Anticipated to Grow US$303.6 bn by 2020

Transparency Market Research has published a new report on the global home healthcare market. As per the report, the global home healthcare market is predicted to progress from US$176.1 bn in 2013 to US$303.6 bn by 2020. The report, titled ‘Global Home Healthcare Market – Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020’, states that the global home healthcare market is expected to expand at a 8.10% CAGR during the period between 2014 and 2020.

Read Report @ https://www.transparencymarketresearch.com/home-healthcare-market.html

The rising prevalence of chronic diseases is expected to result in an increase in the uptake of household medical services and medical devices. Technological advancements are predicted to increase the adoption of household medical devices in the years to come. The changing demographic profile supports acceptance of household medical devices and services. Although the high cost of household medical devices is expected to restrict the growth of the global home healthcare market, availability of various options is predicted to propel the global home healthcare market in the years to come. Acquisitions and mergers by the leading players are also anticipated to create growth opportunities for the global home healthcare market in the years to come.

The global home healthcare market is segmented on the basis of device type, service, and geography. Based on geography, the global home healthcare market is divided into Europe, North America, Asia Pacific, and Rest of the World. The global home healthcare market is dominated by North America, followed by Europe and Asia Pacific. The U.S. FDA, in 2007, announced that it would deliver close oversight of home healthcare devices and equipment in the country and its expenditure was noted to be US$57.6 bn. The North America home healthcare market is predicted to expand at a rapid pace due to factors such as the increasing prevalence of chronic diseases and presence of a large number of home healthcare service providers.

In 2013, Europe accounted for 25% of the total market to be in the second position in the global home healthcare market. Asia Pacific is predicted to expand at a 7.0% CAGR during the period from 2014 to 2020. The Europe home healthcare market is expected to expand due to factors such as high prevalence of cardiovascular diseases and diabetes. Based on device type, the global home healthcare market is classified into diagnostics and monitoring home devices, therapeutics home healthcare devices, home mobility assist devices, and medical supplies.

By service, the global home healthcare market is classified into rehabilitation services, telehealth and telemedicine services, infusion therapy services, respiratory therapy services, and unskilled home healthcare services. Although the diagnostics and monitoring devices segment accounted for the largest share in 2013, the therapeutics home healthcare sector is expected to expand at a 10.0% CAGR during the period from 2014 to 2020.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=300

The global home healthcare market is highly competitive and fragmented. With periodic mergers and acquisitions, the leading companies are predicted to maintain their dominant positions in the years to come. Some of the leading companies in the global home healthcare market are Teleflex Corporation, Medtronic, Inc., ResMed, Inc., Invacare Corporation, Johnson & Johnson, Omron Healthcare, Inc., F. Hoffman-La Roche Ltd., Abbott Laboratories, Cardinal Health, Gentiva Health Services, Inc., and Praxair Technologies, Inc.

Global Disinfectors Market Surge Valuation US$3.1 bn By 2020

A report published by Transparency Market Research (TMR), titled “Disinfectors Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020” pegs the overall value of the global disinfectors market at US$1.6 bn in 2013. By 2020, the market is anticipated to reach US$3.1 bn, expanding at a robust 10.20% CAGR.

Disinfection is a crucial procedure performed across healthcare institutions to ensure proper hygiene in their campuses. The demand for disinfectors is, therefore, significantly high in healthcare facilities including clinics, hospitals, institutes, laboratories, and elder care facilities. With the increasing incidence of hospital-acquired infections (HAI), the demand for disinfectors is poised to increase exponentially in forthcoming years.

Read Report @ https://www.transparencymarketresearch.com/disinfectors-market.html

Using unclean medical instruments or not sterilizing them properly before use can have adverse effects on patients, ultimately leading them to develop HAIs. The use of disinfectors has therefore significantly increased over the past few years to prevent HAIs from occurring. As the number of surgeries conducted over time increases, the demand for disinfectors will also grow in response. The most common types of products available in the global disinfector market include flusher disinfectors, endoscope reprocessors, and washer disinfectors. Of these, the washer disinfectors and endoscope reprocessors account for the largest share in the market, and are likely to remain the leading market segments throughout the report’s forecast period. The increasing use of a plethora of medical instruments and endoscopes due to the growing prevalence of chronic ailments will provide lucrative opportunities for enterprises operating in these market segments to capitalize on in the near future.

The TMR report is compiled with the intent to provide a holistic overview of the global disinfectors market, covering the market’s trajectory from the ground up. It studies the factors that in the near future will boost the market or restrain it in detail. The report also evaluates the prospects exhibited by each market segment to help stakeholders determine their future course of action.

For instance, the report segments the global disinfectors market into pharmaceuticals, elder care, life sciences companies, hospitals and clinics, and healthcare facilities based on usage. The demand for disinfectors from clinics and hospitals is likely to rise significantly during the forecast period, states the report. “The increasing number of hospitals, coupled with the rising number of surgical practices, will boost the global disinfectors market”, states a lead TMR analyst.

Regionally, North America and Europe collectively accounted for a dominant 70% of the global disinfectors market in 2013, in terms of revenue. However, between 2014 and 2020, Asia Pacific is likely to exhibit the fastest growth in demand for disinfectors due to the rising prevalence of several contagious diseases, increasing geriatric population, and increasing investment in the healthcare sector.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2947

To provide a comprehensive overview of the market, the report also profiles some of the leading enterprises such as STERIS Corporation, Getinge Group, OLYMPUS CORPORATION, Advanced Sterilization Products Services, Inc., Belimed Group, and others.